AstraZeneca to buy Bristol stake in diabetes venture for up to $4.1 bln

LONDON Thu Dec 19, 2013 2:58am EST

LONDON Dec 19 (Reuters) - AstraZeneca has agreed to buy Bristol-Myers Squibb's stake in a diabetes joint venture between the two drugmakers for an initial $2.7 billion plus up to $1.4 billion in additional payments.

The move, announced by the two partners on Thursday, will bulk up AstraZeneca's thin drug portfolio and give Bristol more funds to invest in other areas, such as cancer, where it is developing promising therapies tapping into the immune system.

Speculation that such a deal might be on the cards was fuelled last month after Bristol decided to exit diabetes drug research.

The Bristol-AstraZeneca diabetes joint venture includes the oral medicines Onglyza, Kombiglyze and Forxiga, as well as the injectable treatments Bydureon and Byetta. Last week, the venture received a boost when an advisory panel to the U.S. Food and Drug Administration endorsed its new diabetes pill dapagliflozin.

We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/
Comments (1)
In the latest medical school trials of Transmax Resveratrol as a preventative and treatment for Type 2 Diabetes not only were plasma glucose and insulin sensitivity improved, but other important health parameters including body weight, LDL cholesterol, and even blood pressure were substantially reduced. it is clear that a consensus of compelling peer-reviewed evidence now exists which supports the consideration of the inclusion of Resveratrol into the standard treatment protocol for Type 2 Diabetes and probably Type 1 Diabetes as well.

Dec 19, 2013 10:54am EST  --  Report as abuse
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.